NEW YORK, Feb. 17 (GenomeWeb News) - BioCrossroads, a public-private consortium of life science institutions from central Indiana, said today that it has established a protein center of excellence called the Indiana Centers for Applied Protein Sciences (INCAPS).
The center will provide proteomics tools and services -- including technology validation, protein analysis services, instrumentation, and technical support -- for academic and industry investigators in central Indiana and beyond, BioCrossroads said.
INCAPS is housed at the Indiana University Emerging Technologies Center in downtown Indianapolis. James Ludwig, head of proteomics programs at Eli Lilly, will serve as the founding CEO of the center.
Institutions involved in launching INCAPS include Lilly, Roche Diagnostics, Dow AgroSciences, Indiana University Bloomington, the Indiana University School of Medicine, Purdue University, the City of Indianapolis, the Central Indiana Corporate Partnership, and Inproteo - an alliance of Lilly, Indiana University, and Purdue University set up to commercialize proteomics research and generate spin-off companies.
Lilly has committed $3.2 million to INCAPS in a combination of participation fees, executive support, instrument training, and the prepayment for services to be provided by the center to Lilly through 2006.